The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's stomach endoscopically before being expanded with 550 milliliters of water. “Over the past decade, demand for ...

The Company plans to submit the fourth and final module of the Pre-Market Approval application to the FDA. Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric ...

James Manning / PA Images via Getty Images Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves ...

Allurion’s intragastric balloon has demonstrated yet more positive efficacy and safety results in a study on patients living obesity, though the company continues to struggle with weakening ...

The rate of serious adverse events in Allurion Balloon subjects in the AUDACITY trial was 3.1%, the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon indicated for ...

Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss ... devices comprising electrotherapy, ultrasound, phototherapy, traction, hot ...

which is the first FDA pivotal trial for an intragastric balloon to report outcomes beyond nine months, involved 550 subjects. They were randomized to receive either two cycles of the Allurion ...

(NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the safety and efficacy of the Allurion ...